UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                          Washington, D. C. 20549

                                 FORM 10-Q

     (Mark One)
(X)   Quarterly Report Under Section 13 or 15(D) of The Securities Exchange
      Act of 1934 For Quarter Ended March 31, 2002

                       OR

( )   Transition Report Pursuant to Section 13 or 15(d) of The  Securities
      Exchange Act of 1934


                       Commission File Number 0-275


                              Allen Organ Company
          (Exact name of registrant as specified in its charter)



     Pennsylvania                       23-1263194
  (State of Incorporation)      (I.R.S. Employer Identification No.)



  150 Locust Street, P. O. Box 36, Macungie, Pennsylvania      18062-0036
  (Address of principal executive offices)                     (Zip Code)



Registrant's telephone number, including area code           610-966-2200


Indicate  by  check mark whether the registrant (1) has filed  all  reports
required to be filed by Section 13 or 15(d) of the Securities Exchange  Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject  to
such filing requirements for the past 90 days.

                         Yes    X        No _____

Number of shares outstanding of each of the issuer's classes of common
stock, as of April 24, 2002:

                    Class A - Voting          83,864 shares
                    Class B - Non-voting   1,086,457 shares
<PAGE>
                            ALLEN ORGAN COMPANY

                                   INDEX


Part I  Financial Information

   Item 1.Financial Statements
          Consolidated Condensed Statements of Income for the three months
          ended March 31, 2002 and 2001

          Consolidated Condensed Balance Sheets at March 31, 2002 and
          December 31, 2001

          Consolidated Condensed Statements of Cash Flows for the three
          months ended March 31, 2002 and 2001

          Notes to Consolidated Condensed Financial Statements

   Item 2.Management's Discussion and Analysis of Financial Condition and
          Results of Operations

   Item 3.Quantitative and Qualitative Disclosures About Market Risk

Part II    Other Information

   Item 6.Exhibits and Reports on Form 8-K

   Signatures
<PAGE>
PART I  FINANCIAL INFORMATION
   ITEM 1.FINANCIAL STATEMENTS

                   ALLEN ORGAN COMPANY AND SUBSIDIARIES
                CONSOLIDATED CONDENSED STATEMENTS OF INCOME
                                (Unaudited)

                                                    For the 3 Months Ended:
                                                   3/31/2002        3/31/2001

         Net Sales                                $15,977,488      $13,259,398

         Costs and Expenses
           Costs of sales                           9,349,060        9,877,547
           Selling, general and administrative      3,509,633        4,300,272
           Research and development                 1,967,117        2,196,308
           Impairment of VIR, Inc. goodwill and
            intangibles                                --            1,400,000
          Total Costs and Expenses                 14,825,810       17,774,127

         Income (Loss) from Operations              1,151,678       (4,514,729)

         Other Income and (Expense)
           Interest and other income                  141,861          354,143
           Interest expense                            --             (151,029)
           Minority interests in
            consolidated subsidiaries                  --               50,123
          Total Other Income and Expense              141,861          253,237

         Income (Loss) Before Taxes                 1,293,539       (4,261,492)

         Income Tax Provision (Benefit)               362,000       (1,636,000)

         Net Income (Loss)                        $   931,539      $(2,625,492)

         Basic and Diluted Earnings (Loss) Per Share    $0.80           $(2.24)

         Shares Used in Per Share Calculation       1,170,321        1,170,592

         Dividends Per Share - Cash                     $0.14            $0.14

         Total Comprehensive Income (Loss)        $   922,233      $(2,726,504)

                          See accompanying notes.
<PAGE>
                   ALLEN ORGAN COMPANY AND SUBSIDIARIES
                   CONSOLIDATED CONDENSED BALANCE SHEETS

                                                March 31, 2002     Dec 31,2001
                     ASSETS                      (Unaudited)        (Audited)

Current Assets
  Cash                                           $ 5,686,644      $ 4,449,998
  Investments Including Accrued Interest          11,696,735       11,609,416
  Accounts Receivable, net of reserves of
   $414,796 and $350,492, respectively             8,852,653        9,947,842
  Inventories:
     Raw Materials                                 5,433,885        5,515,815
     Work in Process                               6,537,130        6,249,775
     Finished Goods                                5,039,761        4,720,318
      Total Inventories                           17,010,776       16,485,908
  Income Taxes Prepaid and Receivable                859,394        1,106,214
  Prepaid Expenses                                   592,939          386,421
  Deferred Income Tax Benefits                     1,560,454        1,561,138
     Total Current Assets                         46,259,595       45,546,937
Property, Plant and Equipment                     26,882,133       26,600,965
  Less Accumulated Depreciation                  (15,657,110)     (15,109,416)
     Total Property, Plant and Equipment          11,225,023       11,491,549
Other Assets
  Inventory Held for Future Service                  819,187          811,249
  Note Receivable from Related Party               2,397,291        1,997,107
  Cash Value of Life Insurance                     2,173,566        2,173,566
  Deferred Income Tax Benefits                     2,022,725        2,022,725
  Goodwill, net                                      194,523          194,523
  Intangible Assets, net                           2,053,032        2,218,504
  Other Assets                                        16,092           16,092
     Total Other Assets                            9,676,416        9,433,766
     Total Assets                                $67,161,034      $66,472,252

         LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES
Current Liabilities
  Accounts Payable                               $ 2,594,927      $ 2,750,251
  Other Accrued Expenses                           2,204,072        1,973,154
  Customer Deposits                                2,870,571        2,978,023
     Total Current Liabilities                     7,669,570        7,701,428
Noncurrent Liabilities
  Deferred and Other Noncurrent Liabilities          788,023          707,769
  Accrued Pension Costs                            1,627,997        1,748,040
     Total Noncurrent Liabilities                  2,416,020        2,455,809
     Total Liabilities                            10,085,590       10,157,237

STOCKHOLDERS' EQUITY
  Common Stock   2002               2001
     Class A   127,232 shares;    127,232 shares     127,232          127,232
     Class B 1,410,761 shares;  1,410,761 shares   1,410,761        1,410,761
  Capital in Excess of Par Value                  12,905,650       12,903,610
  Retained Earnings
     Balance, Beginning                           55,237,713       59,977,002
     Net Income (Loss)                               931,539       (4,083,810)
     Dividends - Cash 2002 and 2001                 (163,845)        (655,479)
     Balance, End                                 56,005,407       55,237,713
  Accumulated Other Comprehensive Income          (1,383,605)      (1,374,300)
     Sub-total                                    69,065,445       68,305,016
  Treasury Stock
     2002-43,368 Class A shares
         324,304 Class B shares                  (11,990,001)            --
     2001-43,368 Class A shares
         324,304 Class B shares                        --         (11,990,001)
  Total Stockholders' Equity                      57,075,444       56,315,015
  Total Liabilities and Stockholders' Equity     $67,161,034      $66,472,252
                          See accompanying notes.
<PAGE>
                   ALLEN ORGAN COMPANY AND SUBSIDIARIES
              CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
                                (Unaudited)

                                                    For the 3 Months Ended:
                                                   3/31/2002       3/31/2001
  CASH FLOWS FROM OPERATING ACTIVITIES
   Net income (loss)                              $  931,539     $(2,625,492)
   Adjustments to reconcile net income (loss)
    to net cash provided by (used in)
    operating activities
     Depreciation and amortization                   715,946         795,812
     Loss from impairment of VIR, Inc. goodwill and
      intangibles, included in operating expenses      --          1,400,000
     Minority interest in consolidated subsidiaries    --            (50,123)
   Change in assets and liabilities
     Accounts receivable                           1,095,189       2,761,029
     Inventories                                    (532,806)     (1,218,259)
     Income taxes prepaid and receivable             246,820      (1,481,743)
     Prepaid expenses                               (206,518)       (389,907)
     Prepaid pension costs                             --            (28,576)
     Deferred income tax benefits                        684          44,000
     Accounts payable                               (155,324)       (346,090)
     Accrued expenses                                230,918        (953,518)
     Customer deposits                              (107,452)         18,834
     Additional Pension Liability                   (120,043)           --
     Deferred and other noncurrent liabilities        80,254          34,853
       Net Cash Provided by (Used In)
        Operating Activities                       2,179,207      (2,039,180)

  CASH FLOW FROM INVESTING ACTIVITIES
     Increase in note receivable                    (400,184)       (399,058)
     Net additions to plant and equipment           (281,168)       (630,634)
     Additions to goodwill and intangible assets      (2,780)           --
     Net (purchase) sale of short term investments   (96,624)        (19,971)
       Net Cash (Used In) Provided by
        Investing Activities                        (780,756)     (1,049,663)

  CASH FLOWS FROM FINANCING ACTIVITIES
     Proceeds from bank loans                          --          2,200,000
     Proceeds from sale of subsidiary stock            2,040          96,333
     Reacquired Class B common shares                  --             (5,735)
     Dividends paid in cash                         (163,845)       (163,886)
       Net Cash (Used In) Provided by
        Financing Activities                        (161,805)      2,126,712

  NET INCREASE (DECREASE) IN CASH                  1,236,646        (962,131)

  CASH, BEGINNING                                  4,449,998       2,712,368

  CASH, ENDING                                    $5,686,644     $ 1,750,237


            SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION
  Cash paid for:
     Income Taxes                                 $  115,180     $    94,000
     Interest                                     $    --        $   151,029

                          See accompanying notes.
<PAGE>
                   ALLEN ORGAN COMPANY AND SUBSIDIARIES

           NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

1. Interim Financial Statements
   The  results of operations for the interim periods shown in this  report
   are  not necessarily indicative of results to be expected for the fiscal
   year.   In  the opinion of management, the information contained  herein
   reflects  all  adjustments necessary to make the results  of  operations
   for  the interim periods a fair statement of such operations.  All  such
   adjustments are of a normal recurring nature.

   Certain notes and other information have been condensed or omitted  from
   the  interim financial statements presented in the Quarterly  Report  on
   Form  10-Q.   Therefore, these financial statements should  be  read  in
   conjunction with the Company's 2001 Annual Report on Form 10-K.

2. New Accounting Standards
   Effective  January 1, 2002, the Company adopted the following Statements
   issued by the Financial Accounting Standards Board neither of which  had
   a material affect on the Company's financial statements.

     SFAS  142,  "Goodwill  and  Other Intangible Assets"  -  replaces  the
      requirement to amortize intangible assets with indefinite  lives  and
      goodwill  with a requirement for an impairment test.  The  amount  of
      goodwill  amortization  included in the operating  expenses  for  the
      three months ended March 31, 2001 was $32,407.

     SFAS  144,  "Accounting for the Impairment or Disposal  of  Long-Lived
      Assets"  -  Establishes  one accounting model,  used  for  long-lived
      assets  to  be  held  and  used, disposed of  by  sale  or  otherwise
      disposed.

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND
RESULTS OF OPERATIONS.

Liquidity and Capital Resources:
    Cash  flows from operating activities increased during the three  month
period  ended March 31, 2002, primarily due to higher operating  income  in
the Musical Instruments and Data Communications segments and a decrease  in
accounts receivable primarily in the Data Communications segment.

Sales and Operating Income

                                             For the 3 Months Ended:
                                             3/31/2002     3/31/2001
    Net Sales to Unaffiliated Customers
      Musical Instruments                  $ 6,306,201    $ 5,923,121
      Data Communications                    8,666,294      3,600,016
      Electronic Assemblies                    585,855      3,293,360
      Audio Equipment                          419,138        442,901
       Total                               $15,977,488    $13,259,398

    Intersegment Sales
      Musical Instruments                  $    72,409    $    16,291
      Data Communications                         --          132,126
      Electronic Assemblies                     75,861          --
      Audio Equipment                           42,397         10,127
       Total                               $   190,667    $   158,544

    Income (Loss) from Operations
      Musical Instruments                  $   823,910    $   414,141
      Data Communications                      699,852     (5,005,185)
      Electronic Assemblies                   (237,802)       287,388
      Audio Equipment                         (134,282)      (211,073)
       Total                               $ 1,151,678    $(4,514,729)

Musical Instruments Segment

    Sales increased $383,080 in the first quarter of 2002 when compared  to
the  same period in 2001.  While the order rate and number of units shipped
in  the  first quarter of 2002 was approximately equal to 2001,  the  first
quarter  of  2002  sales were higher due the shipment of models  that  have
higher average selling prices.

   Gross profit margins increased to 32.8% of sales in the first quarter of
2002  from  29.1%  in  the same period in 2001.  This increase  is  due  to
changes in product mix and the increased sales level.

     Selling,   general  and  administrative  expenses  and  research   and
development  expenditures were approximately equal to the  same  period  in
2001.

Data Communications Segment

    This  segment's sales in the first quarter of 2002 increased $5,066,278
when compared to the same period in 2001.  The 2002 sales increased due  to
new  product introductions and from the redirection of the Company's  sales
and marketing efforts away from CLECs to other Data Communications markets.
The  2001  sales  were negatively affected by the significant  and  overall
slowdown  in the Data Communications market.

    Gross  profit margins in the first quarter of 2002 increased  to  52.6%
compared to 30.1% in the same period of 2001 due to the higher sales volume
over  which  to absorb fixed costs and less discounting of selling  prices.
The  2001  gross  profit margins were negatively affected  by  $360,000  of
additional non-cash inventory valuation adjustments recorded at  VIR,  Inc.
for slow moving and obsolete inventory associated with discontinued product
lines.

    Sales and marketing expenditures decreased approximately $327,000 (16%)
in  the  first  quarter of 2002 when compared to the same  period  in  2001
primarily due to cost reduction programs implemented during 2001.

    General  and  administrative  expenses  and  research  and  development
expenses  decreased  approximately  $358,000  (38%)  and  $184,000   (10%),
respectively in the first quarter of 2002 when compared to the same  period
in  2001.  These decreases are primarily related to cost savings related to
the  combination of the VIR Linear Switch operations into Eastern Research,
Inc.  (ERI) during 2001 and an overall reduction in the number of personnel
serving  these functions, part of an expense reduction program  implemented
to bring the Company's costs inline with business conditions.

    The  combination  of increased sales, higher gross  margins  and  lower
operating costs resulted in operating income of approximately $700,000  for
this  segment  in  the first quarter of 2002 compared to a large  operating
loss  in  the  same  period  of 2001.  The 2001  operating  loss  was  also
negatively  affected by inventory valuation adjustments  and  a  charge  to
write  down  the  goodwill  and  intangible assets  of  VIR,  Inc  totaling
$1,760,000.   While  this segments order rate has stabilized,  the  Company
remains cautious, as future sales visibility is limited.

Electronic Assemblies Segment

    Sales  for the first quarter of 2002 decreased $2,707,505 when compared
to  the  same  period  in 2001 from lower order volume from  the  Company's
contract  manufacturing customers, which have been affected by the economic
slowdown.   The order rate is expected to continue at this lower  level  in
future quarters.

    The gross profit margin was a loss of approximately $(154,000) (27%) in
the first quarter of 2002 primarily due to lower sales volume over which to
absorb  fixed  costs.  The gross profit percentage was  12%  in  the  first
quarter  of  2001.  Selling, general and administrative expenses  decreased
slightly when compared to the same period in 2001.

Audio Equipment Segment

    Sales for the first quarter of 2002 decreased slightly when compared to
the same period in 2001.  Gross profit margins in the first quarter of 2002
decreased  to  28.7%  as compared to 31.7% for the  same  period  in  2001,
primarily  due to lower sales volume over which to absorb fixed  costs  and
lower  margins  on  wholesale  sales to  dealers  that  made  up  a  larger
percentage of sales in the first quarter of 2002.

    Selling,  general and administrative costs for the period decreased  in
the first quarter of 2002 when compared to the same period in 2001.

    Legacy  Audio  has  historically sold its  products  through  a  direct
marketing  program.  The Company believes that this method of  distribution
has  limited its ability to penetrate the broader market.  Legacy has begun
implementing  plans to distribute its products through a  more  traditional
dealer network.  The Company has added independent retail dealers and  will
continue  to  do  so  in a conservative manner to build  a  quality  dealer
network.   During this period Legacy has been shifting marketing  resources
to  the  new  method  of distribution.  In addition, the  general  economic
slowdown  has slowed the sales of consumer goods.  This has resulted  in  a
sales  decrease in direct sales that has not been entirely offset by dealer
sales.

    Legacy's  speaker  cabinets  are currently  manufactured  at  both  the
Company's  Macungie PA plant, as well as a smaller facility in  Springfield
IL.  The Company plans to consolidate all Legacy production at the Macungie
plant  by  the  third quarter of 2002.  In Addition, Legacy's sales  office
will  be located in Macungie.  The effect of this consolidation is expected
to be immaterial.

Other Income and Expense

    Investment income for the three months ended March 31, 2002  was  lower
than the same period in 2001 due to lower invested balances and lower rates
of return available on invested funds.

Income Taxes

    The tax provision for the three months ended March 31, 2002 is based on
the  estimated  effective tax rate for the year, which  is  less  than  the
statutory rate due to tax credits and exempt income.

Factors that May Affect Operating Results

   The statements contained in this report on Form 10-Q that are not purely
historical are forward looking statements within the meaning of Section 27A
of  the  Securities Act of 1933 and Section 21E of the Securities  Exchange
Act  of  1934,  including statements regarding the Company's  expectations,
hopes,  intentions  or  strategies regarding the future.   Forward  looking
statements  include:  statements  regarding  future  products  or   product
development; statements regarding future research and development  spending
and  the  Company's marketing and product development strategy,  statements
regarding  future  production  capacity.  All  forward  looking  statements
included in this document are based on information available to the Company
on  the  date hereof, and the Company assumes no obligation to  update  any
such  forward looking statements.  Readers are cautioned not to place undue
reliance  on  these forward looking statements, which reflect  management's
opinions  only as of the date hereof.  Readers should carefully review  the
risk  factors described in other documents the Company files from  time  to
time  with  the  Securities and Exchange Commission, including  the  Annual
Report  on  Form  10-K.  It is important to note that the Company's  actual
results  could  differ  materially  from  those  in  such  forward  looking
statements.  Some of the factors that could cause actual results to  differ
materially are set forth below.

   The  Company  has  experienced and expects  to  continue  to  experience
fluctuations  in  its  results  of operations.   Factors  that  affect  the
Company's  results of operations include the volume and  timing  of  orders
received, changes in global economics and financial markets, changes in the
mix of products sold, market acceptance of the Company's and its customer's
products,  competitive pricing pressures, global currency  valuations,  the
availability  of  electronic  components that the  Company  purchases  from
suppliers,  the Company's ability to meet increasing demand, the  Company's
ability  to  introduce new products on a timely basis, the  timing  of  new
product  announcements and introductions by the Company or its competitors,
changing  customer requirements, delays in new product qualifications,  the
timing and extent of research and development expenses and fluctuations  in
manufacturing yields.  As a result of the foregoing or other factors, there
can  be  no  assurance  that  the  Company  will  not  experience  material
fluctuations  in future operating results on a quarterly or  annual  basis,
which  would  materially  and  adversely  affect  the  Company's  business,
financial condition and results of operations.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

   No change from information disclosed in the Company's 2001 annual
   report on form 10-K.

PART II    OTHER INFORMATION
  Item 6.  Exhibits and Reports on Form 8-K
   (b)     No  reports on Form 8-K were filed during  the  quarter
           ended March 31, 2002.

SIGNATURES
Pursuant  to the requirements of the Securities Exchange Act of  1934,  the
registrant  has duly caused this report to be signed on its behalf  by  the
undersigned thereunto duly authorized.
                                            Allen Organ Company
                                                (Registrant)

Date: April 25, 2002             /s/STEVEN MARKOWITZ
                                 Steven Markowitz, President and Chief
                                 Executive Officer

Date: April 25, 2002             /s/NATHAN S. ECKHART
                                 Nathan S. Eckhart, Vice President-Finance,
                                 Chief Financial and Principal Accounting
                                 Officer